Component
U73122, pharmacological PLC inhibitor
Context-specific entity; species, compartment and exposure are stated on each claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
The PLC inhibitor U73122 reduced the intracellular calcium rise and AMPK/ACC phosphorylation after resveratrol in mouse C2C12 cells.
Experimental context and source evidence
- availability_state
- machinery_impairment Imported condition classification; unverified.
- evidence_access
- Primary full text
- experimental_model
- 50 micromolar resveratrol cell experiments.
- limitations
- Supports PLC involvement; this inhibitor alone does not isolate PLC-epsilon.
- nutrient_topic
- Resveratrol collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Resveratrol
- plain_language
- A phospholipase-linked step lies upstream of calcium signaling.
- primary_references
- Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. · 2012 · https://pubmed.ncbi.nlm.nih.gov/22304913/ · DOI 10.1016/j.cell.2012.01.017
- trigger_kind
- machinery_impairment Imported condition classification; unverified.
Resveratrol: metabolites, target selectivity and cross-nutrient mechanisms (2026-09-19) · lines 270–276
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · 50 micromolar resveratrol cell experiments. · source_derived_draft · unverified_draft
## resveratrol-plc-calcium A phospholipase-linked step lies upstream of calcium signaling. The PLC inhibitor U73122 reduced the intracellular calcium rise and AMPK/ACC phosphorylation after resveratrol in mouse C2C12 cells. Model: 50 micromolar resveratrol cell experiments. Limitations: Supports PLC involvement; this inhibitor alone does not isolate PLC-epsilon. Evidence access: Primary full text Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. · 2012 · https://pubmed.ncbi.nlm.nih.gov/22304913/ · DOI 10.1016/j.cell.2012.01.017
Complete structured claim and evidencePLC inhibitor U73122 attenuated CLA-induced calcium accumulation, inflammatory signaling and impaired glucose uptake.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- Human adipocyte inhibitor experiment.
- limitations
- Broad inhibitor evidence does not isolate PLC-gamma1 as necessary.
- nutrient_topic
- CLA collection; isomer, preparation, species, exposure and manipulation remain explicit. · Conjugated linoleic acid / CLA isomer family
- plain_language
- A phospholipase-sensitive step linked membrane signaling to calcium.
- primary_references
- The phospholipase C inhibitor U73122 attenuates trans-10, cis-12 conjugated linoleic acid-mediated inflammatory signaling and insulin resistance in human adipocytes. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23468551/ · DOI 10.3945/jn.112.173161
Conjugated linoleic acid: isomers, signaling, nutrient interactions and discovery (2026-09-19) · lines 174–180
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Human adipocyte inhibitor experiment. · source_derived_draft · unverified_draft
## cla-plc-block A phospholipase-sensitive step linked membrane signaling to calcium. PLC inhibitor U73122 attenuated CLA-induced calcium accumulation, inflammatory signaling and impaired glucose uptake. Model: Human adipocyte inhibitor experiment. Limitations: Broad inhibitor evidence does not isolate PLC-gamma1 as necessary. Evidence access: Primary abstract The phospholipase C inhibitor U73122 attenuates trans-10, cis-12 conjugated linoleic acid-mediated inflammatory signaling and insulin resistance in human adipocytes. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23468551/ · DOI 10.3945/jn.112.173161
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.